It's saying, let's have a review of it. It's saying, let's do an economic modelling of it, so we know what would happen, ... It doesn't eliminate anything, but it doesn't close the door to changing the way we fund at least a part of health.
Obviously there will have to be operating cost dollars provided, because we wouldn't build them to see them sit idle.
What happened in the States, while regrettable, I'm sure nobody regrets it more than that company, is something that I believe will not have a bearing on this file.
We're not closing the door to looking at the insurance-based model for one part or for several parts of the health-care system,
I don't believe that private delivery systems will be anxious to take on some of the high-cost services, such as expensive cancer treatments or transplant surgeries. They're more likely to look at what is profitable.
The vision is to have a strong public system, the vision is to make sure that there's health care when and where you need it, ... And we're paying attention.
This company, from what I've been told, has a very strong reputation, has a world-wide reputation for doing excellent financial analysis, ... We were very pleased that they applied.